Related references
Note: Only part of the references are listed.Targeted therapies for advanced thyroid cancer
Efisio Puxeddu et al.
CURRENT OPINION IN ONCOLOGY (2011)
Biochemical Mechanisms of Resistance to Small-Molecule Protein Kinase Inhibitors
Ratika Krishnamurty et al.
ACS CHEMICAL BIOLOGY (2010)
Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site
Doriano Fabbro et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2010)
Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRα, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants
Ellen Weisberg et al.
BLOOD (2010)
Aurora kinase inhibitors
J. J. E. M. Kitzen et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2010)
Molecular pathogenesis of tyrosine kinase resistance in chronic myeloid leukemia
Paul La Rosee et al.
CURRENT OPINION IN HEMATOLOGY (2010)
Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer
Rafael Rosell et al.
CURRENT OPINION IN ONCOLOGY (2010)
Standard treatment of Ph+ CML in 2010: how, when and where not to use what BCR/ABL1 kinase inhibitor?
Peter Valent
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2010)
CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity
Henrik Green et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib
Neil P. Shah et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
A Type-II Kinase Inhibitor Capable of Inhibiting the T315I Gatekeeper Mutant of Bcr-Abl
Hwan Geun Choi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Inhibitors of phosphatidylinositol-3-kinase in cancer therapy
Nathan T. Ihle et al.
MOLECULAR ASPECTS OF MEDICINE (2010)
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors
Jianming Zhang et al.
NATURE (2010)
Kinase inhibitors attract attention as oral rheumatoid arthritis drugs
Alisa Opar
NATURE REVIEWS DRUG DISCOVERY (2010)
Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy
Klaus Strebhardt
NATURE REVIEWS DRUG DISCOVERY (2010)
Integrating molecular diagnostics into anticancer drug discovery
Istvan Petak et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Computational solutions to large-scale data management and analysis
Eric E. Schadt et al.
NATURE REVIEWS GENETICS (2010)
Kinase mutations in human disease: interpreting genotype-phenotype relationships
Piya Lahiry et al.
NATURE REVIEWS GENETICS (2010)
Anticipating drug resistance in the MAP kinase pathway
Ronen Marmorstein
PIGMENT CELL & MELANOMA RESEARCH (2010)
New technologies for autoimmune disease monitoring
Holden T. Maecker et al.
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY (2010)
Targeting the cancer kinome through polypharmacology
Zachary A. Knight et al.
NATURE REVIEWS CANCER (2010)
Non-ATP competitive protein kinase inhibitors as anti-tumor therapeutics
Lindsay O. Kirkland et al.
BIOCHEMICAL PHARMACOLOGY (2009)
Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis
Jennifer L. Snead et al.
BLOOD (2009)
FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Tyrosine Kinase Inhibitors Display a Nonoverlapping Profile of Resistance Mutations In vitro
Nikolas von Bubnoff et al.
CANCER RESEARCH (2009)
Equally Potent Inhibition of c-Src and Abl by Compounds that Recognize Inactive Kinase Conformations
Markus A. Seeliger et al.
CANCER RESEARCH (2009)
Clinical pharmacokinetics of tyrosine kinase inhibitors
Nielka P. van Erp et al.
CANCER TREATMENT REVIEWS (2009)
Targeting mTOR with rapamycin One dose does not fit all
David A. Foster et al.
CELL CYCLE (2009)
Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway
Kim-Son H. Nguyen et al.
CLINICAL LUNG CANCER (2009)
Kinome signaling through regulated protein-protein interactions in normal and cancer cells
Tony Pawson et al.
CURRENT OPINION IN CELL BIOLOGY (2009)
The road less traveled: modulating signal transduction enzymes by inhibiting their protein-protein interactions
Michelle R. Arkin et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2009)
Kinase Inhibitors as Potential Therapeutics for Acute and Chronic Neurodegenerative Conditions
G. D. Cuny
CURRENT PHARMACEUTICAL DESIGN (2009)
Mechanisms of resistance to FLT3 inhibitors
S. Haihua Chu et al.
DRUG RESISTANCE UPDATES (2009)
Ruboxistaurin: PKC-β inhibition for complications of diabetes
Ronald P. Danis et al.
EXPERT OPINION ON PHARMACOTHERAPY (2009)
Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants
Sara Redaelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Hybrid Compound Design To Overcome the Gatekeeper T338M Mutation in cSrc
Matthaeus Getlik et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Microfluidic single cell arrays to interrogate signalling dynamics of individual, patient-derived hematopoietic stem cells
Shannon L. Faley et al.
LAB ON A CHIP (2009)
Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells
Duncan H. Mak et al.
MOLECULAR CANCER THERAPEUTICS (2009)
A Conserved Salt Bridge in the G Loop of Multiple Protein Kinases Is Important for Catalysis and for In Vivo Lyn Function
Rina Barouch-Bentov et al.
MOLECULAR CELL (2009)
FIP1L1-PDGFRα D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRα T674I eosinophilic leukemia with single agent sorafenib
E. Lierman et al.
LEUKEMIA (2009)
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
Wenjun Zhou et al.
NATURE (2009)
A new screening assay for allosteric inhibitors of cSrc
Jeffrey R. Simard et al.
NATURE CHEMICAL BIOLOGY (2009)
Selectivity and therapeutic inhibition of kinases: to be or not to be?
Kamran Ghoreschi et al.
NATURE IMMUNOLOGY (2009)
Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC
Helena Linardou et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Imatinib and beyond-exploring the full potential of targeted therapy for CML
Alfonso Quintas-Cardama et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
Pasi A. Jaenne et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Cell cycle kinases as therapeutic targets for cancer
Silvia Lapenna et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Targeting innate immunity protein kinase signalling in inflammation
Matthias Gaestel et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity
Z. Tang et al.
ONCOGENE (2009)
A conserved protonation-dependent switch controls drug binding in the Abl kinase
Yibing Shan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Conformational disturbance in Abl kinase upon mutation and deregulation
Roxana E. Iacob et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
MEK1 mutations confer resistance to MEK and B-RAF inhibition
Caroline M. Emery et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients
Ketan S. Gajiwala et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Protein kinase inhibitors: contributions from structure to clinical compounds
Louise N. Johnson
QUARTERLY REVIEWS OF BIOPHYSICS (2009)
Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance
D. Bixby et al.
Hematology-American Society of Hematology Education Program (2009)
Targeting cancer with small molecule kinase inhibitors
Jianming Zhang et al.
NATURE REVIEWS CANCER (2009)
Structure-based view of epidermal growth factor receptor regulation
Kathryn M. Ferguson
ANNUAL REVIEW OF BIOPHYSICS (2008)
Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations
Egle Avizienyte et al.
BIOCHEMICAL JOURNAL (2008)
Molecular basis explanation for imatinib resistance of BCR-ABL due to T3151 and P-loop mutations from molecular dynamics simulations
Tai-Sung Lee et al.
CANCER (2008)
Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110α
Eli R. Zunder et al.
CANCER CELL (2008)
Palomid 529, a Novel Small-Molecule Drug, Is a TORC1/TORC2 Inhibitor That Reduces Tumor Growth, Tumor Angiogenesis, and Vascular Permeability
Qi Xue et al.
CANCER RESEARCH (2008)
Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations
Seiji Yano et al.
CANCER RESEARCH (2008)
Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor
Toshirou Nishida et al.
CANCER SCIENCE (2008)
Structure and dynamic regulation of Src-family kinases
J. R. Engen et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2008)
Molecular basis of drug resistance in Aurora kinases
Fiona Girdler et al.
CHEMISTRY & BIOLOGY (2008)
Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma
James Bean et al.
CLINICAL CANCER RESEARCH (2008)
EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation
Torsten Trowe et al.
CLINICAL CANCER RESEARCH (2008)
Doing more than just the structure-structural genomics in kinase drug discovery
Brian D. Marsden et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2008)
Acquired resistance to tyrosine kinase inhibitors during cancer therapy
Jeffrey A. Engelman et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2008)
Therapeutic strategies for inhibiting oncogenic BRAF signaling
Ensar Halilovic et al.
CURRENT OPINION IN PHARMACOLOGY (2008)
Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges
Laura L. Rokosz et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2008)
Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours
J. Lasota et al.
HISTOPATHOLOGY (2008)
Overcoming kinase resistance in chronic myeloid leukemia
Francis Lee et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2008)
T-cell-targeted signaling inhibitors
Jonghwa Won et al.
INTERNATIONAL REVIEWS OF IMMUNOLOGY (2008)
Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib
Navratna Vajpai et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor
Michael C. Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism
J. Liu et al.
LEUKEMIA (2008)
A quantitative analysis of kinase inhibitor selectivity
Mazen W. Karaman et al.
NATURE BIOTECHNOLOGY (2008)
High-throughput kinase profiling as a platform for drug discovery
David M. Goldstein et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Activation of tyrosine kinases by mutation of the gatekeeper threonine
Mohammad Azam et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2008)
Commentary: Novel therapies for cancer: Why dirty might be better
Tito Fojo
ONCOLOGIST (2008)
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Cai-Hong Yun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors
Ken-Hong Lim et al.
MEDICAL ONCOLOGY (2008)
Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-Mutant lung cancer reveals novel treatment strategies
Zhiwei Yu et al.
CANCER RESEARCH (2007)
Flying under the radar:: the new wave of BCR-ABL inhibitors
Alfonso Quintas-Cardama et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Crystal structure of the T315I mutant of abl kinase
Tianjun Zhou et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2007)
Roots of imatinib resistance: A question of self-renewal?
Andreas Burchert
DRUG RESISTANCE UPDATES (2007)
A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding
Marie A. Bogoyevitch et al.
DRUG DISCOVERY TODAY (2007)
EGFR kinase domain mutations - functional impact and relevance for lung cancer therapy
D. Irmer et al.
ONCOGENE (2007)
Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study
Arghya Ray et al.
BLOOD (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia
Ellen Weisberg et al.
NATURE REVIEWS CANCER (2007)
Discovery of novel 2,3-diarylfuro[2,3-b]pyridin-4-amines as potent and selective inhibitors of Lck:: Synthesis, SAR, and pharmacokinetic properties
Matthew W. Martin et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
Patterns of somatic mutation in human cancer genomes
Christopher Greenman et al.
NATURE (2007)
Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity
Cai-Hong Yun et al.
CANCER CELL (2007)
Resistance to c-KIT kinase inhibitors conferred by V654A mutation
Kathryn G. Roberts et al.
MOLECULAR CANCER THERAPEUTICS (2007)
High-throughput oncogene mutation profiling in human cancer
Roman K. Thomas et al.
NATURE GENETICS (2007)
Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors
Jeffrey Jie-Lou Liao
JOURNAL OF MEDICINAL CHEMISTRY (2007)
KIT mutations in GIST
Jonathan A. Fletcher et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2007)
Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia
Sandra W. Cowan-Jacob et al.
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY (2007)
Ba/F3 cells and their use in kinase drug discovery
Markus Warmuth et al.
CURRENT OPINION IN ONCOLOGY (2007)
Epidermal growth factor receptor mutations in lung cancer
Sreenath V. Sharma et al.
NATURE REVIEWS CANCER (2007)
Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants
Brian J. Skaggs et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Quantitative structure-pharmacokinetic/pharmacodynamic relationships
Donald E. Mager
ADVANCED DRUG DELIVERY REVIEWS (2006)
Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism
Alexandr P. Kornev et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Comparison of imatinib, mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen:: high efficacy of drug combinations
Heather A. Bradeen et al.
BLOOD (2006)
Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the AN kinase inhibitor nilotinib (AMN107)
Nikolas von Bubnoff et al.
BLOOD (2006)
Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib
Ian J. Griswold et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Rational design of inhibitors that bind to inactive kinase conformations
Y Liu et al.
NATURE CHEMICAL BIOLOGY (2006)
An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor
Xuewu Zhang et al.
CELL (2006)
A Src-like inactive conformation in the Abl tyrosine kinase domain
Nicholas M. Levinson et al.
PLOS BIOLOGY (2006)
Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase
B Nagar et al.
MOLECULAR CELL (2006)
Allosteric inhibitors of Bcr-abl-dependent cell proliferation
FJ Adrián et al.
NATURE CHEMICAL BIOLOGY (2006)
Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the aurora kinase inhibitor VX-680
MA Young et al.
CANCER RESEARCH (2006)
Gefitinib response of erlotinib-refractory lung cancer involving meninges - role of EGFR mutation
NW Choong et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR
DW Bell et al.
NATURE GENETICS (2005)
Second-generation kinase inhibitors
BM Klebl et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2005)
The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation
SW Cowan-Jacob et al.
STRUCTURE (2005)
Structure and inhibition of the human cell cycle checkpoint kinase, Wee1A kinase: An atypical tyrosine kinase with a key role in CDK1 regulation
CJ Squire et al.
STRUCTURE (2005)
A cell-based screening strategy that predicts mutations in oncogenic tyrosine kinases - Implications for clinical resistance in targeted cancer treatment
N von Bubnoff et al.
CELL CYCLE (2005)
Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance
MR Burgess et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
PTC Wan et al.
CELL (2004)
Imatinib (STI571) resistance in chronic myelogenous leukemia: Molecular basis of the underlying mechanisms and potential strategies for treatment
SW Cowan-Jacob et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2004)
Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors
F Carlomagno et al.
ONCOGENE (2004)
Overriding imatinib resistance with a novel ABL kinase inhibitor
NP Shah et al.
SCIENCE (2004)
Strategies to overcome resistance to targeted protein kinase inhibitors
H Daub et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL
M Azam et al.
CELL (2003)
A myristoyl/phosphotyrosine switch regulates c-Abl
O Hantschel et al.
CELL (2003)
Structural basis for the autoinhibition of c-Abl tyrosine kinase
B Nagar et al.
CELL (2003)
Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop
S Roumiantsev et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
NP Shah et al.
CANCER CELL (2002)
The conformational plasticity of protein kinases
M Huse et al.
CELL (2002)
Crystal structure of a transition state mimic of the catalytic subunit of cAMP-dependent protein kinase
Madhusudan et al.
NATURE STRUCTURAL BIOLOGY (2002)
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
ME Gorre et al.
SCIENCE (2001)
Dynamic coupling between the SH2 and SH3 domains of c-Src and hck underlies their inactivation by C-terminal tyrosine phosphorylation
MA Young et al.
CELL (2001)
Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase
T Schindler et al.
SCIENCE (2000)
Share Paper
